A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.
Comparison of olaparib vs. physician's choice of single agent standard of care non-platinum
based chemotherapy in patients with germline Breast Cancer susceptibility gene (gBRCA)
mutated ovarian cancer who have progressed at least 6 months after the last platinum based
chemotherapy. Patient should have received at least 2 prior lines of platinum based
chemotherapy. The aim of the study is to assess the efficacy and safety of olaparib tablets.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society